OMX Nordic 40
|
2 349,69
|
-9,03
|
-0,38 %
|
Analysen zu OMX Nordic 40-Werten
| 17.03.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 14.03.25 | Novo Nordisk Buy | UBS AG | |
| 13.03.25 | Volvo AB Sector Perform | RBC Capital Markets | |
| 13.03.25 | Volvo AB Overweight | JP Morgan Chase & Co. | |
| 12.03.25 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 12.03.25 | AstraZeneca Buy | UBS AG | |
| 11.03.25 | Novo Nordisk Buy | Deutsche Bank AG | |
| 11.03.25 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 11.03.25 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 10.03.25 | AstraZeneca Buy | UBS AG | |
| 10.03.25 | Novo Nordisk Buy | UBS AG | |
| 10.03.25 | Novo Nordisk Market-Perform | Bernstein Research | |
| 10.03.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 10.03.25 | Novo Nordisk Market-Perform | Bernstein Research | |
| 10.03.25 | AstraZeneca Buy | UBS AG | |
| 07.03.25 | Novo Nordisk Buy | UBS AG | |
| 07.03.25 | Hennes & Mauritz AB Neutral | UBS AG | |
| 04.03.25 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.03.25 | AstraZeneca Outperform | Bernstein Research | |
| 03.03.25 | Novo Nordisk Buy | UBS AG | |
| 03.03.25 | Hennes & Mauritz AB Sector Perform | RBC Capital Markets | |
| 28.02.25 | Volvo AB Buy | Deutsche Bank AG | |
| 27.02.25 | ABB Hold | Jefferies & Company Inc. | |
| 26.02.25 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 26.02.25 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 26.02.25 | AstraZeneca Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 26.02.25 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 26.02.25 | Volvo AB Buy | UBS AG | |
| 25.02.25 | Novo Nordisk Market-Perform | Bernstein Research | |
| 25.02.25 | Hennes & Mauritz AB Equal Weight | Barclays Capital | |
| 24.02.25 | ABB Neutral | UBS AG | |
| 24.02.25 | ABB Sector Perform | RBC Capital Markets | |
| 24.02.25 | Novo Nordisk Buy | UBS AG | |
| 24.02.25 | Hennes & Mauritz AB Sector Perform | RBC Capital Markets | |
| 24.02.25 | Volvo AB Buy | Goldman Sachs Group Inc. | |
| 20.02.25 | Nokia Overweight | JP Morgan Chase & Co. | |
| 20.02.25 | AstraZeneca Outperform | Bernstein Research | |
| 20.02.25 | Novo Nordisk Market-Perform | Bernstein Research | |
| 20.02.25 | Hennes & Mauritz AB Underweight | JP Morgan Chase & Co. | |
| 19.02.25 | AstraZeneca Overweight | JP Morgan Chase & Co. |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.